A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

키워드

참고문헌 (58)

1. Vanderstichele H, "Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies", Clin Chem Lab Med, 44, pp.1472~1480 (2006)
2. Shaw LM, "Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects", Ann Neurol, 65, pp.403~413 (2009)
3. Welge V, "Combined CSF tau, p-tau181 and amyloid-beta 38", 40, J Neural Transm, pp.2009, 116[DOI]
4. McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease:recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
5. Albert MS, "The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.270~279 (2011)
6. Dubois B, "Revising the definition of Alzheimer’s disease:a new lexicon", Lancet Neurol, 9, pp.1118~1127 (2010)
7. Weigand SD, "Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid", Alzheimers Dement, 7, pp.133~141 (2011)
8. Grimmer T, "Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid", Biol Psychiatry, 65, pp.927~934 (2009)
9. Strozyk D, "CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study", Neurology, 60, pp.652~656 (2003)
10. Leow AD, "Alzheimer’s disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition", Neuroimage, 45, pp.645~655 (2009)
11. Buerger K, "CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease", Brain, 129, pp.3035~3041 (2006)
12. Blennow K, "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease", Nat Rev Neurol, 6, pp.131~144 (2010)
13. Jack CR Jr, "Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers", Lancet Neurol, 12, pp.207~216 (2013)
14. Vos SJ, "Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI", Neurology, 80, pp.1124~1132 (2013)
15. Riemenschneider M, "Cerebrospinal fluid tau and beta-amyloid 42proteins identify Alzheimer disease in subjects with mild cognitive impairment", Arch Neurol, 59, pp.1729~1734 (2002)
16. Buchhave P, "Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia", Arch Gen Psychiatry, 69, pp.98~106 (2012)
17. Hansson O, "Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study", Lancet Neurol, 5, pp.228~234 (2006)
18. Snider BJ, "Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type", Arch Neurol, 66, pp.638~645 (2009)
19. Tabaraud F, "Alzheimer CSF biomarkers in routine clinical setting", Acta Neurol Scand, 125, pp.416~423 (2012)
20. Aisen PS, "Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease", Nat Rev Drug Discov, 12, pp.324~ (2013)
21. 박선아, "알츠하이머병 뇌척수액 생물표지자 다기관 연구를 위한 예비연구", Dementia and Neurocognitive Disorders(대한치매학회지), 12(1), pp.1~8 (2013), 대한치매학회[DOI]
22. Carrillo MC, "Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium", Alzheimers Dement, 9, pp.137~140 (2013)
23. Teunissen CE, "A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking", Neurology, 73, pp.1914~1922 (2009)
24. Vanderstichele H, "Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative", Alzheimers Dement, 8, pp.65~73 (2012)
25. del Campo M, "Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update", Biomark Med, 6, pp.419~430 (2012)
26. Mattsson N, "CSF biomarker variability in the Alzheimer’s Association quality control program", Alzheimers Dement, 9, pp.251~261 (2013)
27. Hampel H, "Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020", Biochem Pharmacol, 88, pp.426~449 (2014)
28. 이은희, "한국의 알츠하이머병 환자에서 아세틸콜린 에스터레이스 억제제의 뇌척수액 베타아밀로이드 1-42 분획과 인산화타우단백 농도에 미치는 효과", 대한신경과학회지, 26(3), pp.224~230 (2008), 대한신경과학회
29. Fagan AM, "Cerebrospinal fluid tau", beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults, 2007, pp.64, 343~349
30. Evans RW, "Complications of lumbar puncture", Neurol Clin, 16, pp.83~105 (1998)
31. Lim TS, "Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers", BMC Neurol, 14, pp.66~ (2014)
32. Bjerke M, "Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid", Int J Alzheimers Dis (2010)
33. Bateman RJ, "Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker", Neurology, 68, pp.666~669 (2007)
34. Moghekar A, "Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort", Arch Neurol, 69, pp.246~250 (2012)
35. Xie L, "Sleep drives metabolite clearance from the adult brain", Science, 342, pp.373~377 (2013)
36. Roh JH, "Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer’s disease pathology", Sci Transl Med, 4, pp.122~ (2012)
37. Strupp M, "“Atraumatic” Sprotte needle reduces the incidence of post-lumbar puncture headaches", Neurology, 57, pp.2310~2312 (2001)
38. Tung CE, "Cost comparison between the atraumatic and cutting lumbar puncture needles", Neurology, 78, pp.109~113 (2012)
39. Arendt K, "Atraumatic lumbar puncture needles: after all these years, are we still missing the point?", Neurologist, 15, pp.17~20 (2009)
40. Ahmed SV, "Post lumbar puncture headache:diagnosis and management", Postgrad Med J, 82, pp.713~716 (2006)
41. Hong Z, "DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease", Brain, 133, pp.713~726 (2010)
42. Kang JH, "Association of cerebrospinal fluid β-amyloid 1-42, T-tau, Ptau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease", JAMA Neurol, 70, pp.1277~1287 (2013)
43. You JS, "The impact of blood contamination on the proteome of cerebrospinal fluid", Proteomics, 5, pp.290~296 (2005)
44. Blennow K, "Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid", serum albumin ratio, 1993, pp.33, 126~128
45. Blennow K, "Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid", J Neural Transm Park Dis Dement Sect, 5, pp.5~15 (1993)
46. Simonsen AH, "Proteomic investigations of the ventriculo-lumbar gradient in human CSF", J Neurosci Methods, 191, pp.244~248 (2010)
47. Lewczuk P, "Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides", Clin Chem, 52, pp.332~334 (2006)
48. Pica-Mendez AM, "Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20", Clin Chim Acta, 411, pp.1833~ (2010)
49. Perret-Liaudet A, "Risk of Alzheimer’s disease biological misdiagnosis linked to cerebrospinal collection tubes", J Alzheimers Dis, 31, pp.13~20 (2012)
50. Lehmann S, "Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis", Alzheimers Dement, 10(5), pp.S390~S394 (2014)
51. Toombs J, "Amyloid-beta 42adsorption following serial tube transfer", Alzheimers Res Ther, 6, pp.5~ (2014)
52. Simonsen AH, "Pre-analytical factors influencing the stability of cerebrospinal fluid proteins", J Neurosci Methods, 215, pp.234~240 (2013)
53. Zimmermann R, "Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics", J Alzheimers Dis, 25, pp.739~745 (2011)
54. Rosenling T, "The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF)", J Proteome Res, 8, pp.5511~5522 (2009)
55. Toombs J, "Identification of an important potential confound in CSF AD studies: aliquot volume", Clin Chem Lab Med, 51, pp.2311~2317 (2013)
56. Schoonenboom NS, "Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid:implications for use in clinical practice", Clin Chem, 51, pp.189~195 (2005)
57. Bibl M, "Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment:indication of carrier-mediated epitope masking of amyloid beta peptides", Electrophoresis, 25, pp.2912~2918 (2004)
58. Sjögren M, "Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values", Clin Chem, 47, pp.1776~1781 (2001)

관련 논문AI추천